MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind’s double-digit

#SCPH MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

www.stocktitan.net/news/SCPH/mann-kind-comp...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ASST, #BSY, #BYND, #RUM, #SCPH

#OptionFlow #OptionsTrading #Trading

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases MannKind Corporation (Nasdaq: MNKD) has announced the acquisition of scPharmaceuticals (Nasdaq: SCPH) in a deal valued up to $360 million. The transaction includes an upfront payment of $5.35 per share plus a CVR worth up to $1.00 per share, representing a 36% premium to SCPH's 90-day VWAP.The acquisition brings FUROSCIX®, an FDA-approved treatment for fluid overload in chronic heart failure and chronic kidney disease patients, with a $10+ billion U.S. market opportunity. FUROSCIX achieved strong H1 2025 performance with net sales of $27.8 million, up 96% year-over-year. The combined company projects an annualized revenue run rate of over $370 million based on Q2 2025 results.The deal is expected to close in Q4 2025, strengthening MannKind's position in cardiometabolic and lung diseases while accelerating double-digit revenue growth through multiple commercial assets including Afrezza®, FUROSCIX, and V-Go®.

#SCPH MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

www.stocktitan.net/news/SCPH/mann-kind-to-a...

scPharmaceuticals Strengthens IP Portfolio with 5 New Patents for Innovative Heart Failure Treatment Patent allowances cover SCP-111 furosemide formulation for treating edema in heart failure and kidney disease patients. FDA filing expected this quarter. Learn more.

#SCPH scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111

www.stocktitan.net/news/SCPH/sc-pharmaceuti...

Earnings: SCPH Reports 93% Revenue Growth as New FDA Approval Slashes Treatment Time from 5 Hours to Seconds Q1 results reveal 13,900 FUROSCIX doses filled, 4,200 unique prescribers, and FDA approval for CKD treatment. New autoinjector cuts delivery time to seconds. See metrics.

#SCPH scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/SCPH/sc-pharmaceuti...

scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update scPharmaceuticals (SCPH) reported strong Q4 and full-year 2024 results, with Q4 FUROSCIX revenue reaching $12.2 million (up 99% YoY) and full-year revenue of $36.3 million (up 167% YoY). The company filled approximately 13,300 FUROSCIX doses in Q4 2024, a 23% increase from Q3.Key highlights include FDA approval for FUROSCIX's expanded label to treat edema in chronic kidney disease patients, with launch planned for April 2025. The company reported about 3,800 unique prescribers through year-end 2024, showing 23% growth from Q3. The gross-to-net discount was 19% for Q4 and 16% for full-year 2024.Financial position remains strong with $75.7 million in cash and cash equivalents as of December 31, 2024. However, the company reported a net loss of $18.8 million in Q4 and $85.1 million for the full year 2024.

#SCPH scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/SCPH/sc-pharmaceuti...

scPharmaceuticals Readies Major Financial Update: Q4 and Full Year Results Coming March 19 scPharmaceuticals schedules comprehensive earnings presentation with management insights and business updates. Join the webcast March 19 at 4:30 PM ET for latest cardiorenal developments.

#SCPH scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

www.stocktitan.net/news/SCPH/sc-pharmaceuti...

Whooping cough is most dangerous for infants, but vaccination protects everyone—pregnant people, infants, children, teens, and adults. Protect yourself and the babies around you. Get vaccinated! #WhoopingCough #VaccinateToProtect #CommunityHealth #Sacramento #SacramentoCountyPublicHealth #SCPH

scPharmaceuticals Reports Explosive 167% Revenue Growth, FUROSCIX Shipments Hit Record High scPharmaceuticals delivers stellar Q4 results with $12.3M revenue, 99% YoY growth. FUROSCIX shipments surge 23% as company expands distribution network and eyes 2025 growth initiatives.

#SCPH scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/SCPH/sc-pharmaceuti...

#SCPH scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/SCPH/sc-pharmaceuti...

News; ( NASDAQ: #SCPH ) scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure

#StockMarket #News

NEWS: ( NASDAQ: #SCPH ) scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors

#StockMarket #News

Breaking News: ( NASDAQ: #SCPH ) scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

#StockMarket #News